Shots:

• The INMARK study involves assessing of Ofev (nintedanib) vs PBO in 347 patients with IPF for 12 wks.- followed by an open label period of 40 wks.
• The study resulted @12 wks lower rate of FVC decline (18.5 vs 13.1)- with no rate of change in CRPM- 29% of the subjects experienced FVC decline of ≥10%  
• Ofev is a tyrosine kinase inhibitor- shown to slow disease progression by reducing lung function decline and was also included in updated international treatment guidelines for IPF in 2017- approved in 70+ countries including the US- EU and Japan for IPF

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247